LPAR1 and neoplasm: Remarkably, a study by Murph et al. revealed that LPA, via LPA1–3 engagement and intracellular activation of the PI3K/Akt signaling pathway, inhibits p53 activity and protects tumor cells from actinomycin D-induced apoptosis [64], indicating that LPA is potentially an inducer of drug resistance in tumors.